NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. by Adelstein, David et al.
UC San Diego
UC San Diego Previously Published Works
Title
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.
Permalink
https://escholarship.org/uc/item/8bd6h33b
Journal
Journal of the National Comprehensive Cancer Network : JNCCN, 15(6)
ISSN
1540-1405
Authors
Adelstein, David
Gillison, Maura L
Pfister, David G
et al.
Publication Date
2017-06-01
DOI
10.6004/jnccn.2017.0101
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 15   Number 6 | June 2017
761
NCCN
Guidelines® 
Insights
Head and Neck Cancers 
C
E
 J J r l f t  ti l r si  r t r   l     r   J  
From 1Case Comprehensive Cancer Center/University Hospitals 
Seidman Cancer Center and Cleveland Clinic Taussig Cancer In-
stitute; 2The University of Texas MD Anderson Cancer Center; 
3Memorial Sloan Kettering Cancer Center; 4University of Ala-
bama at Birmingham Comprehensive Cancer Center; 5Siteman 
Cancer Center at Barnes-Jewish Hospital and Washington Uni-
versity School of Medicine; 6Duke Cancer Institute; 7Yale Cancer 
Center/Smilow Cancer Hospital; 8Massachusetts General Hospi-
tal Cancer Center; 9Moffitt Cancer Center; 10Vanderbilt-Ingram 
Cancer Center; 11Stanford Cancer Institute; 12The Sidney Kimmel 
Comprehensive Cancer Center at Johns Hopkins; 13St. Jude Chil-
dren’s Research Hospital/The University of Tennessee Health 
Science Center; 14Mayo Clinic Cancer Center; 15Dana-Farber/ 
Brigham and Women’s Cancer Center; 16Roswell Park Cancer 
Institute; 17Huntsman Cancer Institute at the University of 
Utah; 18University of Colorado Cancer Center; 19Fred & Pamela 
Buffett Cancer Center; 20City of Hope Comprehensive Cancer 
Center; 21UC San Diego Moores Cancer Center; 22Robert H. 
Lurie Comprehensive Cancer Center of Northwestern Universi-
ty; 23Fox Chase Cancer Center; 24The Ohio State University Com-
prehensive Cancer Center–James Cancer Hospital and Solove 
Research Institute; 25Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance; 26University of Wisconsin Carbone 
Cancer Center; 27University of Michigan Comprehensive Cancer 
Center; 28UCSF Helen Diller Family Comprehensive Cancer Cen-
ter; and 29National Comprehensive Cancer Network.
*Provided content development and/or authorship assistance.
Please Note
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proaches to treatment. The NCCN Guidelines® Insights 
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line Panel discussion, including the literature reviewed.
These NCCN Guidelines Insights do not represent the 
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plication of the NCCN Guidelines and NCCN Guidelines 
Insights and disclaims any responsibility for their applications 
or use in any way.
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Guidelines are available at NCCN.org.
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Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommenda-
tions for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are 
also provided for occult primary of the head and neck (H&N), and separate algorithms have been developed by the panel for very 
advanced H&N cancers. These NCCN Guidelines Insights summarize the panel’s discussion and most recent recommendations re-
garding the increase in human papillomavirus–associated oropharyngeal cancer and the availability of immunotherapy agents for 
treatment of patients with recurrent or metastatic H&N cancer.
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NCCN Categories of Evidence and Consensus
 
Category 1: Based upon high-level evidence, there 
is uniform NCCN consensus that the intervention 
is appropriate.
Category 2A: Based upon lower-level evidence, there 
is uniform NCCN consensus that the intervention is 
appropriate.
Category 2B: Based upon lower-level evidence, there 
is NCCN consensus that the intervention is appro-
priate.
Category 3: Based upon any level of evidence, there 
is major NCCN disagreement that the intervention 
is appropriate.
All recommendations are category 2A unless otherwise 
noted.
Clinical trials: NCCN believes that the best management 
for any cancer patient is in a clinical trial. Participation in 
clinical trials is especially encouraged.
Overview
Treatment is complex for patients with head and 
neck (H&N) cancers. The specific site of disease, 
stage, and pathologic findings guide treatment (eg, 
the appropriate surgical procedure, radiation tar-
gets, dose and fractionation, indications for systemic 
therapy). Single-modality treatment with surgery or 
radiation therapy (RT) is generally recommended 
for the approximately 30% to 40% of patients who 
present with early-stage disease (stage I or II). The 
2 most commonly used modalities, surgery and RT, 
result in similar survival in these individuals. The 
choice of surgery or RT is often based on local in-
stitutional expertise and/or perceived relative mor-
bidity of these treatment options. With evolving 
techniques of systemic therapy/RT and less invasive 
surgery, morbidity is also a moving target. Combined 
modality therapy is generally recommended for the 
approximately 60% of patients with locally or re-
gionally advanced disease at diagnosis. Participa-
tion in clinical trials is a preferred or recommended 
Version 2.2017 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any 
form without the express written permission of NCCN®. ORPH-1
aH&P should include documentation and quantification (pack 
years smoked) of tobacco use history. Smoking cessation 
counseling as clinically indicated. All current smokers should be 
advised to quit smoking, and former smokers should be advised 
to remain abstinent from smoking. For additional cessation 
support and resources, smokers can be referred to the NCCN 
Guidelines for Smoking Cessation and www.smokefree.gov.
bScreen for depression (See NCCN Guidelines for Distress 
Management).
Base of tongue/tonsil/posterior pharyngeal wall/soft palate
WORKUP CLINICAL STAGING
• H&Pa,b including a complete head and neck exam; 
mirror and fi beroptic examination as clinically 
indicated
• Biopsy of primary site or fi ne-needle aspiration 
(FNA) of the neck
• Tumor human papillomavirus (HPV) testing 
recommendedc
• Chest CTd (with or without contrast) as clinically 
indicated
• CT with contrast and/or MRI with contrast of 
primary and neck  
• Consider FDG-PET/CT for stage III-IV disease
• Dental evaluation,e including panorex as clinically 
indicated
• Nutrition, speech and swallowing evaluation/
therapy, and audiogram as clinically indicatedf
• EUA with endoscopy as clinically indicated
• Pre-anesthesia studies
Multidisciplinary consultation as clinically indicated
T1-2, N0-1
T3-4a, N0-1
Any T, N2-3
T4b, any N, 
or 
Unresectable nodal disease 
or 
Unfi t for surgery
Metastatic (M1) disease 
at initial presentation
See Treatment of Primary and Neck (ORPH-2)
See Treatment of Primary and Neck (ORPH-3)
See Treatment of Primary and Neck (ORPH-4)
See Treatment of Very Advanced
Head and Neck Cancer (ADV-1)
See Treatment of Very Advanced Head
and Neck Cancer (ADV-2)
cP16 expression is highly correlated with HPV status and is widely available. HPV in situ 
hybridization or PCR-based assay is also available. Although not used to guide treatment, 
HPV testing is valuable prognostically. The results of HPV testing should not change 
management decisions except in the context of a clinical trial.
dChest CT is recommended for advanced nodal disease to screen for distant metastases, 
and for select patients who smoke to screen for lung cancer. See NCCN Guidelines for 
Lung Cancer Screening.
eSee Principles of Dental Evaluation and Management (DENT-A).
fSee Principles of Nutrition: Management and Supportive Care (NUTR-A).
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Version 2.2017 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any 
form without the express written permission of NCCN®. ORPH-2
gSee Principles of Radiation Therapy (ORPH-A).
hSee Principles of Surgery (SURG-A).
iSee Principles of Systemic Therapy (CHEM-A). 
jAdverse features: extracapsular nodal spread, positive margins, pT3 or pT4 
primary, N2 or N3 nodal disease, nodal disease in levels IV or V, perineural 
invasion, vascular embolism (lymphovascular invasion) (See Discussion).
Base of tongue/tonsil/posterior pharyngeal wall/soft palate
CLINICAL 
STAGING
TREATMENT OF PRIMARY AND NECK ADJUVANT TREATMENT
Recurrent 
or 
Persistent 
Disease 
(See ADV-3)
Follow-up
(See FOLL-A)
T1-2, N0-1
Defi nitive RTg
or
Transoral or open 
resection of primary 
± ipsilateral or bilateral 
neck dissectionh
For T2, N1 only,
RTg + systemic 
therapyi (category 2B 
for systemic therapy) 
or
or
Multimodality clinical trials
No adverse featuresj
Adverse 
featuresj
Extracapsular 
spread ± 
positive margin
Positive margin
Other risk 
features
Systemic therapy/RTg,i,k
Re-resectionl (preferred)
or 
RTg
or 
Consider systemic therapy/RTg,i
RTg
or 
Consider systemic therapy/RTg,i
kThe recommendations for patients at high risk with extracapsular 
spread + positive margins are based on randomized studies involving 
patients for whom the HPV status of their tumors was not specified.
lConsider re-resection to achieve negative margins, if feasible.
See Follow-Up Recommendations Post 
Chemoradiation or RT (FOLL-A, 2 of 2)
See Follow-Up Recommendations Post 
Chemoradiation or RT (FOLL-A, 2 of 2)
Recurrent or Persistent 
Disease (See ADV-3)
Recurrent or Persistent 
Disease (See ADV-3)
treatment option in many situations. Patients treated 
at high-volume centers tend to have better outcomes 
relative to patients treated at low-volume centers.1,2 
Revisions to the NCCN Clinical Practice Guidelines 
in Oncology (NCCN Guidelines) for H&N Cancers 
in recent years have taken into account the increase 
in human papillomavirus (HPV)–associated oropha-
ryngeal cancer, as well as the recent availability of 
immunotherapy agents for patients with recurrent or 
metastatic disease.
HPV and H&N Cancer
HPV infection is associated with an estimated 4.8% 
of global cancers.3 HPV is now well accepted as a 
cause of squamous cancers of the oropharynx (par-
ticularly cancers of the tonsils and tongue base).4–11 
The overall incidence of HPV-positive H&N can-
cers is increasing in the United States, whereas the 
incidence of HPV-negative (primarily tobacco- and 
alcohol-caused) cancer is decreasing.12 Patients with 
HPV-associated H&N cancer tend to be younger.11,13 
The HPV-attributable fraction in newly diagnosed 
oropharyngeal cancer is estimated at 60% to 70% 
in the United States and parts of the European 
Union.12,14–17 Oral HPV type 16 (HPV16) infection 
increases the risk of oropharyngeal cancer4,10,18,19 and 
a strong causal relationship has been established4,18; 
HPV types 18, 31, and 33 are responsible for the vast 
majority of the remaining fraction.11 Expression of 
HPV E6 and E7 oncogenes inactivates the tumor-
suppressor proteins p53 and pRb, respectively, which 
leads to the development of cancer.20
Prophylactic HPV vaccination strongly de-
creased the incidence of cervical intraepithelial 
neoplasia in prospective clinical trials.21,22 Recent 
data from one of these trials suggest that HPV vac-
cination has the potential to prevent HPV-attribut-
ed oropharyngeal cancer.23 An unplanned analysis 
demonstrated a statistically significantly lower prev-
alence of oral HPV 16/18 infection 4 years after vac-
cination among HPV-vaccinated versus hepatitis A– 
© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 15   Number 6 | June 2017
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Version 2.2017 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any 
form without the express written permission of NCCN®.
CHEM-A 
2 OF 5
See References on CHEM-A 3 of 5
PRINCIPLES OF SYSTEMIC THERAPY
• The choice of systemic therapy should be individualized based on patient characteristics (PS, goals of therapy).  
• Unless otherwise specifi ed, regimens listed below can be used for either nasopharyngeal or non-nasopharyngeal cancer.
Recurrent, Unresectable, or Metastatic 
(with no surgery or RT option)
• Combination therapy
Cisplatin or carboplatin/5-FU/cetuximab30 (non-nasopharyngeal) (category 1)
Cisplatin or carboplatin/docetaxel31 or paclitaxel32 
Cisplatin/cetuximab33 (non-nasopharyngeal)
Cisplatin/5-FU32,34
Cisplatin or carboplatin/docetaxel/cetuximab35 (non-nasopharyngeal)
Cisplatin or carboplatin/paclitaxel/cetuximab36,37 (non-nasopharyngeal) 
Carboplatin/cetuximab38 (nasopharyngeal)  
Cisplatin/gemcitabine39 (nasopharyngeal) 
Gemcitabine/vinorelbine40 (nasopharyngeal)
• Single agents
Cisplatin33,41
Carboplatin42
Paclitaxel43
Docetaxel44,45
5-FU41
Methotrexate46,47
Cetuximab48 (non-nasopharyngeal) 
Gemcitabine49 (nasopharyngeal)
Capecitabine50  
Afatinib51 (non-nasopharyngeal, if disease progression on or after platinum-containing chemotherapy) (category 2B)
Pembrolizumab52,53 (non-nasopharyngeal, if disease progression on or after platinum-containing chemotherapy)
Nivolumab54 (non-nasopharyngeal, if disease progression on or after platinum-containing chemotherapy) (category 1)
vaccinated women.23 However, no formal prospec-
tive studies of the efficacy of HPV vaccines in the 
prevention of oral HPV infections have been con-
ducted, and therefore further studies are warranted.
HPV Testing
The association of tumor HPV status with patient 
prognosis has led to clinical utility (discussed later). 
However, there are currently no diagnostic tests with 
regulatory approval. A few HPV testing options are 
available for use in the clinical setting. Expression of 
p16 as detected by immunohistochemistry (IHC) is 
a widely available surrogate biomarker that has very 
good agreement with HPV status as determined by 
HPV E6/E7 mRNA expression.24–26 Other tests in-
clude HPV detection through PCR and in situ hy-
bridization (ISH).24,26 Sensitivity of IHC staining for 
p16 and PCR-based assay is high, although specific-
ity is highest for ISH.26 A validation study of HPV 
testing methods showed that the sensitivity and 
specificity of p16 IHC was 96.8% and 83.8%, respec-
tively, with the sensitivity and specificity of HPV16 
ISH being 88.0% and 94.7%.24 Agreement between 
p16 IHC and ISH was good. The reduced specific-
ity for p16 IHC may have been due to the presence 
of p16-positive tumors that do not have evidence 
of HPV DNA, whereas the reduced sensitivity for 
HPV16 ISH may been due to the presence of other 
high-risk HPV types in the tumor. Due to variations 
in sensitivity and specificity values of testing options, 
multiple methods may be used in combination for 
HPV detection.11,26–28 Sufficient pathologic material 
for HPV testing can be obtained through fine-needle 
aspiration.11,29
NCCN Recommendations: For the 2016 update, the 
panel revised the footnote regarding HPV testing as 
part of the evaluation for oropharyngeal cancer to 
take into account that p16 IHC is widely available 
and highly correlated with HPV status (ORPH-1; 
page 763). The footnote was also revised to take into 
account the option of using either ISH- or PCR-
based assay. Panel members note that HPV testing 
© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 15   Number 6 | June 2017
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may prompt questions about prognosis (ie, a favor-
able or a less favorable forecast) and sexual history 
that the clinician should be prepared to address. 
HPV and Treatment of Oropharyngeal Cancer
Analyses from clinical trials indicate that patients 
with locally advanced HPV-positive H&N can-
cers experience improved response to treatment 
and overall survival (OS) and progression-free sur-
vival (PFS) when compared with HPV-negative tu-
mors,30–34 with one analysis showing that p16-positive 
nonoropharyngeal squamous H&N cancers have 
a better prognosis compared with p16-negative 
nonoropharyngeal cancers.35 Treatment response is 
improved in patients receiving both chemoradia-
tion30,31 and conventional RT.36 A systematic review 
including 56 prospective or retrospective studies 
showed that patients with p16-positive oropharyn-
geal cancer had a better prognosis and fewer rates 
of adverse events compared with those with p16-
negative disease.37 Further, patients with p16-nega-
tive disease had worse outcomes after RT relative to 
surgery (hazard ratio [HR], 1.66; 95% CI, 1.26–2.18; 
P<.001), and this difference was not statistically sig-
nificant for patients with p16-positive disease (HR, 
1.33; 95% CI, 0.94–1.87; P=.114). 
There may also be an association between HPV 
status and survival in patients with recurrent or 
metastatic disease. Retrospective analyses from the 
phase III RTOG 0129 and 0522 trials30,38 included 
patients with disease progression after platinum-
based chemoradiotherapy (n=154) and showed that 
patients with p16-positive disease had greater OS 
relative to those with p16-negative disease (HR, 
0.48; 95% CI, 0.31–0.74; P<.001).33 An archival 
analysis from 2 ECOG trials (E139539 and E330140), 
which included 129 patients with recurrent or meta-
static H&N squamous cell carcinoma, showed that 
both HPV status (12.9 vs 6.7 months for HPV-pos-
itive vs HPV-negative; P=.014) and p16-positive 
disease (11.9 vs 6.7 months for p16-positive vs p16-
negative; P=.027) were associated with greater me-
dian survival.41 These studies provide substantial evi-
dence that there is a clinically relevant prognostic 
difference in recurrent or metastatic disease.
Because patients with locally advanced HPV-
positive oropharyngeal cancer may live longer, late 
toxicity and quality of life are concerns for these 
patients.42,43 Therefore, consensus is increasing that 
HPV status should be used as a stratification factor 
or be addressed in separate trials (HPV-related vs 
-unrelated disease) for which patients with oropha-
ryngeal cancer are eligible.44–46 Some clinicians have 
recently suggested that less-intense treatment may 
be adequate for HPV-positive oropharyngeal cancers 
(ie, deintensification)47; however, the available data 
supporting this assertion are limited by retrospective 
analyses, variability in HPV testing method used, 
and short follow-up periods.42,47–49 Deintensification 
treatment protocols for HPV-associated, locally ad-
vanced oropharyngeal cancer are being investigated 
in ongoing clinical trials. Strategies under active 
investigation include reducing or using response-
stratified RT dose, using RT alone versus chemora-
diation, using less invasive surgical procedures such 
as transoral robotic surgery, using sequential systemic 
therapy/RT, and using immunotherapy and targeted 
therapy agents such as cetuximab.42,43,50 The ECOG-
ACRIN phase II E1308 trial, in which patients with 
stage III–IV HPV16 and/or p16-positive oropha-
ryngeal cancer (N=80) received induction chemo-
therapy followed by reduced-dose RT and weekly ce-
tuximab, recently reported results showing that RT 
deintensification may result in equivalent or similar 
responses in selected patients compared with full-
dose RT.51
The relationship between HPV and other prog-
nostic or predictive factors such as smoking his-
tory and stage has been investigated.52,53 For exam-
ple, analyses of patients with oropharyngeal cancer 
who were enrolled in RTOG 9003 or 0129 (n=165) 
showed that smoking was associated with decreased 
OS and PFS, regardless of p16 status.52 A retrospec-
tive analysis from a clinical trial showed no difference 
in the presence of distant metastasis in patients with 
p16-positive disease compared with those with p16-
negative disease.30 Additional analyses have suggest-
ed that individuals with matted nodes or N2c disease 
may have worse prognosis, and therefore should be 
excluded from deintensification trials.47,54,55
The panel currently recommends adjuvant sys-
temic therapy/RT in patients with squamous cell 
carcinoma of the oropharynx in the presence of the 
adverse pathologic features of extracapsular nodal 
spread with (or without) positive mucosal margins. 
This recommendation is primarily based on results 
from RTOG 9501 and EORTC 22931.56–58 However, 
in a review of published data from these randomized 
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controlled trials, it was noted that the panel’s recom-
mendations are based on studies that did not investi-
gate the impact of HPV or p16 status.59 However, the 
investigators from RTOG 9501 and EORTC 22931 
point out that the prevalence of HPV-positive/p16-
positive tumors was likely to be low in these trials.60 
Other limitations noted in this review included un-
planned subgroup analyses, the grouping of multiple 
H&N subsites, inconsistent quantitative reporting, 
and lack of reporting on tumor and lymph node clas-
sification, treatment effect sizes, multivariable analy-
ses, and quality-of-life outcomes. Therefore, the in-
vestigators who performed this review argued that 
these trials lack the generalizability necessary to ra-
tionalize the use of adjuvant systemic therapy/RT in 
patients with p16-positive disease.
Recent retrospective studies have not observed 
a statistically significant association between extra-
capsular spread and survival in patients with HPV-
positive oropharyngeal cancer.44,53,61–64 For example, 
a study of 220 patients with p16-positive oropharyn-
geal cancer who received surgical resection with or 
without adjuvant treatment showed that the pres-
ence of ≥5 metastatic nodes is associated with disease 
recurrence and survival, but extracapsular spread was 
not significantly associated with outcomes in this 
sample.63 Recent studies of patients with p16-posi-
tive oropharyngeal cancer treated with surgery show 
that soft tissue metastasis may be associated with 
poor survival outcomes, especially in patients with 
T3–T4 disease.53,65 These results suggest that patients 
with p16-positive disease with extracapsular spread 
could potentially be treated differently than those 
with p16-negative disease and extracapsular spread.
NCCN Recommendations: The panel deliberated 
regarding the strength and limitations of the evi-
dence supporting the use of adjuvant systemic ther-
apy/RT in patients with oropharyngeal cancer who 
have extracapsular spread. Before the 2016 update, 
adjuvant systemic therapy/RT for patients with ex-
tracapsular spread was a category 1 recommenda-
tion for cancer of the oropharynx, lip, oral cavity, 
hypopharynx, larynx, and unknown primary. For the 
2016 update, the panel revised its recommendation 
for adjuvant systemic therapy/RT in patients with 
oropharyngeal cancer who have extracapsular spread 
from category 1 to category 2A (see ORPH-2; page 
764; revisions also apply to ORPH-3 and ORPH-4). 
This change in category was based on a lack of high-
quality, prospective clinical evidence and controver-
sy. Adjuvant systemic therapy/RT remains a category 
1 recommendation for patients with other types of 
H&N cancer who have extracapsular spread, includ-
ing HPV-negative oropharynx cancer. Where the 
panel recommends adjuvant systemic therapy/RT for 
patients with oropharyngeal cancer and extracap-
sular spread, a footnote was added noting that this 
treatment recommendation is based on randomized 
studies in which HPV status was unknown, consis-
tent with a conclusion of the review by Sinha et al.59 
Because HPV status is a strong predictor of oro-
pharyngeal cancer prognosis, the AJCC recently re-
leased separate staging systems for p16-positive and 
p16-negative oropharyngeal cancer.66,67 However, as 
the panel meeting to discuss the 2017 NCCN Guide-
lines update was held before publication of the new-
est edition of the AJCC Staging Manual, the most 
recent version of the NCCN Guidelines for Cancer 
of the Oropharynx does not take into account dif-
ferential staging between p16-positive and p16-neg-
ative disease. Deintensification treatment protocols 
for patients with HPV-related oropharyngeal cancer 
are currently being investigated (eg, ClinicalTri-
als.gov identifiers: NCT01154920, NCT01706939, 
NCT01302834, and NCT01855451). Panel mem-
bers urge that patients with HPV-related cancers be 
enrolled in clinical trials evaluating biological and 
treatment-related questions.42,43,68
Immunotherapy for Recurrent 
and Metastatic H&N Cancer
Updates to systemic therapy recommendations made 
in 2016 include the addition of 2 immunotherapy 
agents: nivolumab and pembrolizumab (see CHEM-
A 2 of 5; page 765). Nivolumab, an anti–PD-1 an-
tibody, was assessed in a phase III randomized clini-
cal trial including 361 patients with recurrent H&N 
squamous cell cancer whose disease had progressed 
within 6 months after platinum-based chemo-
therapy.69 With a median follow-up of 5.1 months 
(range, 0–16.8 months), OS was significantly greater 
in patients randomized to receive nivolumab versus 
standard second-line, single-agent systemic therapy 
with either methotrexate, docetaxel, or cetuximab 
(HR, 0.70; 97.73% CI, 0.51–0.96; P=.01). One-
year survival was also greater for patients who re-
ceived nivolumab versus standard therapy (36.0% 
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vs 16.6%, respectively) and the response rate was 
higher (13.3% vs 5.8%, respectively), but median 
PFS was not significantly different between the 
groups (2.0 vs 2.3 months, respectively; P=.32). In 
prespecified exploratory analyses, the OS benefit in 
patients treated with nivolumab appeared to be con-
fined to those with a tumor PD-L1 expression level 
of ≥1% (n=149; 8.7 vs 4.6 months; HR, 0.55; 95% 
CI, 0.36–0.83). In patients with tumor PD-L1 ex-
pression level <1% (n=111), no OS advantage was 
demonstrated for those treated with nivolumab (5.7 
vs 5.8 months; HR, 0.89; 95% CI, 0.54–1.45). Grade 
3 or 4 treatment-related adverse events occurred in 
13.1% of patients who received nivolumab compared 
with 35.1% of those who received standard therapy. 
These results indicate that nivolumab prolongs sur-
vival in patients with recurrent or metastatic squa-
mous cell H&N cancer that has progressed after 
platinum-based chemotherapy compared with those 
who receive standard single-agent systemic therapy.
Pembrolizumab, another anti–PD-1 antibody, 
was initially studied at a dose of 10 mg/kg given ev-
ery 2 weeks in the squamous cell H&N cancer cohort 
of the KEYNOTE-012 trial.70 Clinical activity was 
identified and the possibility that responses could be 
durable was suggested. A lower, fixed-dose schedule 
using pembrolizumab, 200 mg every 3 weeks was sub-
sequently assessed in a phase Ib expansion cohort of 
132 patients with recurrent or metastatic squamous 
cell H&N cancer71; 82% of these patients had pre-
viously received systemic therapy for their recurrent 
or metastatic disease. At 6 months, the OS rate was 
59% and PFS was 23%, with an overall response rate 
of 18%. Observed responses appeared durable, al-
though follow-up was limited (median, 9 months). 
Through scoring both tumor and immune cells, the 
response rate in patients who were PD-L1–positive 
(≥1% expression) was significantly greater than in 
patients who were PD-L1–negative (22% vs 4%, 
respectively; P=.021), and responses were seen in 
both HPV-associated and non–HPV-associated dis-
ease. Pembrolizumab was generally well tolerated, 
with grade 3/4 toxicities reported in only 9%, and no 
treatment-related deaths.70
Based on these studies, nivolumab and pembro-
lizumab received FDA approval in 2016 for use in 
patients with recurrent or metastatic squamous cell 
H&N cancer that has progressed on or after plati-
num-based chemotherapy. The NCCN panel recom-
mends nivolumab for patients with this indication as 
a category 1 recommendation based on high-quality 
evidence,69 whereas pembrolizumab is a category 2A 
recommendation based on results from nonrandom-
ized trials.70,71 Despite the ambiguities of PD-L1 test-
ing and definitions, PD-L1 expression may be as-
sociated with better outcomes from treatment with 
immunotherapy for recurrent or metastatic squa-
mous cell H&N cancer (ie, greater likelihood of re-
sponse to pembrolizumab and greater survival benefit 
in response to nivolumab).
Summary
The incidence of HPV-positive oropharyngeal can-
cer is increasing in the United States, and patients 
with locally advanced HPV-positive H&N cancers 
have improved outcomes compared with those with 
HPV-negative tumors. However, currently there are 
insufficient data to recommend that patients with 
HPV-positive oropharyngeal cancers receive less- 
intense treatment relative to patients with HPV-
negative cancers. HPV status is a prognostic factor, 
and panel members urge that patients with HPV-re-
lated cancers be enrolled in clinical trials evaluating 
biological and treatment-related questions. Evidence 
to support adjuvant systemic therapy/RT for patients 
with oropharyngeal cancer and extracapsular spread 
is based on randomized studies in which HPV status 
was unknown. Other recent updates to the NCCN 
Guidelines for H&N Cancers include the addition of 
the immunotherapy agents nivolumab and pembro-
lizumab for the treatment of patients with recurrent 
or metastatic H&N cancer who have progressed on 
or after platinum-based chemotherapy.
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oral cavity which has progressed 
on cisplatin, which treatment op-
tion is recommended as a category 
1 option in the NCCN Guidelines for 
Head and Neck Cancers?
a. Nivolumab
b. Pembrolizumab
c. Cisplatin/gemcitabine
d. Vinorelbine
e. Cetuximab + concurrent RT
choice questions. Credit cannot be obtained for tests complet-
ed on paper. You must be a registered user on NCCN.org. If you 
are not registered on NCCN.org, click on “New Member? Sign 
up here” link on the left hand side of the Web site to register. 
Only one answer is correct for each question. Once you suc-
cessfully answer all posttest questions you will be able to view 
and/or print your certificate. Software requirements: Internet
Instructions for Completion
To participate in this journal CE activity: 1) review the learning 
objectives and author disclosures; 2) study the education con-
tent; 3) take the posttest with a 66% minimum passing score 
and complete the evaluation at http://education.nccn.org/
node/81262; and 4) view/print certificate. After reading the 
article, you should be able to answer the following multiple-
Posttest Questions
1.  HPV testing options include the following:
a. p16 IHC
b. HPV16 ISH
c. HPV testing by PCR-based assay
d. All of the above
2.  True or False: HPV-positive oropharyngeal cancers generally 
have a worse prognosis when compared with HPV-negative 
oropharyngeal cancers.
3.  For a patient with metastatic squamous cell carcinoma of the 
